June 6, 2018
Study: Medical device tax hurts investment in R&D
Editor's Note:
This study from Iowa State University shows companies have cut funding for research and development (R&D) in response to the medical device tax imposed by the Affordable Care Act.
Since 2013, the 2.3% excise tax has significantly reduced:
- R&D investment by $34 million
- Sales revenue by $188 million
- Gross margins by $375 million
- Earnings by $68 million.
The study, which is the first to look at the actual cost of the tax on manufacturers, found it also affected operating and marketing costs.
Free Daily News
- New studies highlight opportunities to improve pediatric anesthesia safety, comfort
- Social and behavioral factors emerging as key predictors of recovery quality after surgery
- Hospitals being squeezed: Anesthesia workforce gaps, payer cuts threaten surgery access
- CDC layoffs cripple national injury and overdose tracking, leaving prevention efforts in doubt
- The Joint Commission makes nurse staffing a national performance goal for 2026
- Telehealth in limbo: Providers split on continuing Medicare services during shutdown
- States take aim at outpatient facility fees driving higher commercial health costs
- Slower acquisitions, mounting debt reshape Surgery Partners growth outlook
- ASCs surge as hospitals and investors chase outpatient growth
- Nearly half of US physicians now work for large systems: GAO links consolidation to higher costs
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement